Genetic Variants in CPA6 and PRPF31 Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes.

ABSTRACT: Metformin is the first-line treatment for type 2 diabetes (T2D). Although widely prescribed, the glucose-lowering mechanism for metformin is incompletely understood. Here, we used a genome-wide association approach in a diverse group of individuals with T2D from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial to identify common and rare variants associated with HbA_1c response to metformin treatment and followed up these findings in four replication cohorts. Common variants in PRPF31 and CPA6 were associated with worse and better metformin response, respectively (P < 5 × 10^-6), and meta-analysis in independent cohorts displayed similar associations with metformin response (P = 1.2 × 10^-8 and P

SUBMITTER: Rotroff DM 

PROVIDER: S-EPMC6014560 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature